Alzheimer’s Research UK renew their commitment to the Drug Discovery Alliance and pledge £45m
Alzheimer’s Research UK (ARUK) has renewed their commitment to the Drug Discovery Alliance (DDA) for another five years and pledged a £45million investment in the DDA.
ARUK originally launched the Drug Discovery Alliance in 2015 to unite the Universities of Cambridge, Oxford and University College London (UCL) and enable them to turn more early‑stage scientific ideas into potential new treatments.
Dr Sheona Scales, Director of Research at Alzheimer’s Research UK, says:
“This investment represents one of the most important commitments we can make to people affected by dementia. By strengthening the Drug Discovery Alliance, we’re giving more brilliant ideas the chance to become tomorrow’s treatments.”
Find out more about the Drug Discovery Alliance here: https://www.alzheimersresearchuk.org/research/for-researchers/translational-hub/drug-discovery-alliance/